Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation

Transplant Immunology

Volumn 25, Issue 2-3, 2011, Pages 104-111

  Sageshima, Junichiro ^a,b   Ciancio, Gaetano ^a,b   Guerra, Giselle ^a,b   Gaynor, Jeffrey J ^a,b   Cova, Deborah ^a,b   Zarak, Alberto ^a   Chen, Linda ^a,b   Mattiazzi, Adela ^a,b   Kupin, Warren ^a,b   Roth, David ^a,b   Hanson, Lois ^a,b   Livingstone, Alan S ^a,b   Ruiz, Phillip ^a,b   Burke, George W ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Alemtuzumab; Anti thymocyte globulin; Induction therapy; Kidney transplantation; Monoclonal antibody

Indexed keywords

ALEMTUZUMAB; CD16 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; CORTICOSTEROID; DACLIZUMAB; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CD25+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFECT; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG DOSE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; T CELL DEPLETION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTIGENS, CD56; ANTILYMPHOCYTE SERUM; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RECEPTORS, IGG; RETROSPECTIVE STUDIES; THYMOCYTES;

EID: 80052338014     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2011.07.002     Document Type: Article

References (56)

1. Kidney Recipients: immunosuppression use. OPTN/SRTR annual report 2009, http://www.ustransplant.org/annual_reports/current/.
2. Sageshima J., Ciancio G., Chen L., Burke G.W. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics. 2009, 3:319-336.
3. Barth R.N., Janus C.A., Lillesand C.A., Radke N.A., Pirsch J.D., Becker B.N., et al. Outcomes at 3years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006, 19:885-892.
4. Bloom D., Chang Z., Pauly K., Kwun J., Fechner J., Hayes C., et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009, 9:1835-1845.
5. Ciancio G., Burke G.W. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008, 8:15-20.
6. Gallon L., Gagliardini E., Benigni A., Kaufman D., Waheed A., Noris M., et al. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). Clin J Am Soc Nephrol 2006, 1:539-545.
7. Kirk A.D., Hale D.A., Mannon R.B., Kleiner D.E., Hoffmann S.C., Kampen R.L., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003, 76:120-129.
8. Knechtle S.J., Pascual J., Bloom D.D., Torrealba J.R., Jankowska-Gan E., Burlingham W.J., et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009, 9:1087-1098.
9. Knechtle S.J., Pirsch J.D., Fechner H.J.J., Becker B.N., Friedl A., Colvin R.B., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003, 3:722-730.
10. Zhang P.L., Malek S.K., Prichard J.W., Lin F., Yahya T.M., Schwartzman M.S., et al. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without campath-1H (alemtuzumab) induction therapy. Am J Transplant 2005, 5:604-607.
11. Burke G.W., Ciancio G., Figueiro J., Olson L., Gomez C., Rosen A., et al. Can acute rejection be prevented in SPK transplantation?. Transplant Proc 2002, 34:1913-1914.
12. Ruggenenti P., Codreanu I., Cravedi P., Perna A., Gotti E., Remuzzi G. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 2006, 1:546-554.
13. Ciancio G., Burke G.W., Gaynor J.J., Roth D., Sageshima J., Kupin W., et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 2008, 86:67-74.
14. Sageshima J., Ciancio G., Gaynor J.J., Chen L., Guerra G., Kupin W., et al. Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population. Clin Transplant 2011, 25:E132-E135.
15. Shirakawa H., Ishida H., Shimizu T., Omoto K., Iida S., Toki D., et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2010, [Electronic publication ahead of print]. doi:10.1111/j.1399-0012.2010.01384.x.
16. Ciancio G., Burke G.W., Gaynor J.J., Carreno M.R., Cirocco R.E., Mathew J.M., et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005, 80:457-465.
17. Ciancio G., Burke G.W., Gaynor J.J., Roth D., Kupin W., Rosen A., et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24months of follow-up. Clin Transplant 2008, 22:200-210.
18. Ciancio G., Burke G.W., Gaynor J.J., Mattiazzi A., Roohipour R., Carreno M.R., et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004, 78:426-433.
19. Ciancio G., Gaynor J.J., Sageshima J., Chen L., Roth D., Kupin W., et al. Favorable outcomes with machine perfusion and longer pump times in kidney transplantation: a single-center, observational study. Transplantation 2010, 90:882-890.
20. Noris M., Casiraghi F., Todeschini M., Cravedi P., Cugini D., Monteferrante G., et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007, 18:1007-1018.
21. Trzonkowski P., Zilvetti M., Chapman S., Wieckiewicz J., Sutherland A., Friend P., et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008, 8:338-347.
22. Pearl J.P., Parris J., Hale D.A., Hoffmann S.C., Bernstein W.B., McCoy K.L., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005, 5:465-474.
23. van der Windt D.J., Smetanka C., Macedo C., He J., Lakomy R., Bottino R., et al. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys. Am J Transplant 2010, 10:773-783.
24. Goggins W.C., Pascual M.A., Powelson J.A., Magee C., Tolkoff-Rubin N., Farrell M.L., et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003, 76:798-802.
25. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
26. LaCorcia G., Swistak M., Lawendowski C., Duan S., Weeden T., Nahill S., et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009, 87:966-974.
27. Klaus G., Mostert K., Reckzeh B., Mueller T.F. Phenotypic changes in lymphocyte subpopulations in pediatric renal-transplant patients after T-cell depletion. Transplantation 2003, 76:1719-1724.
28. Louis S., Audrain M., Cantarovich D., Schaffrath B., Hofmann K., Janssen U., et al. Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids. Transplantation 2007, 83:712-721.
29. Gurkan S., Luan Y., Dhillon N., Allam S.R., Montague T., Bromberg J.S., et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010, 10:2132-2141.
30. Zand M.S. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006, 82:1387-1395.
31. Zand M.S., Vo T., Huggins J., Felgar R., Liesveld J., Pellegrin T., et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005, 79:1507-1515.
32. Stauch D., Dernier A., Sarmiento Marchese E., Kunert K., Volk H.D., Pratschke J., et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One 2009, 4:e4709.
33. Sener A., Tang A.L., Farber D.L. Memory T-cell predominance following T-cell depletional therapy derives from homeostatic expansion of naive T cells. Am J Transplant 2009, 9:2615-2623.
34. Lo D.J., Weaver T.A., Stempora L., Mehta A.K., Ford M.L., Larsen C.P., et al. Selective targeting of human alloresponsive CD8(+) effector memory T cells based on CD2 expression. Am J Transplant 2011, 11:22-33.
35. Gavin M.A., Clarke S.R., Negrou E., Gallegos A., Rudensky A. Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo. Nat Immunol 2001, 3:33-41.
36. Minamimura K., Gao W., Maki T. CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 2006, 176:4125-4132.
37. Vanasek T.L., Nandiwada S.L., Jenkins M.K., Mueller D.L. CD25+Foxp3+ regulatory T cells facilitate CD4+ T cell clonal anergy induction during the recovery from lymphopenia. J Immunol 2006, 176:5880-5889.
38. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
39. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
40. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
41. Roncador G., Brown P.J., Maestre L., Hue S., Martinez-Torrecuadrada J.L., Ling K.L., et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005, 35:1681-1691.
42. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
43. Gavin M.A., Torgerson T.R., Houston E., DeRoos P., Ho W.Y., Stray-Pedersen A., et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006, 103:6659-6664.
44. Pillai V., Ortega S.B., Wang C.K., Karandikar N.J. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007, 123:18-29.
45. Liu W. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
46. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
47. Lopez M. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006, 17:2844-2853.
48. Feng X., Kajigaya S., Solomou E.E., Keyvanfar K., Xu X., Raghavachari N., et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008, 111:3675-3683.
49. Broady R., Yu J., Levings M.K. ATG-induced expression of FOXP3 in human CD4(+) T cells in vitro is associated with T-cell activation and not the induction of FOXP3(+) T regulatory cells. Blood 2009, 114:5003-5006.
50. Bloom D.D., Chang Z., Fechner J.H., Dar W., Polster S.P., Pascual J., et al. CD4+CD25+FOXP3+regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008, 8:793-802.
51. Pascual J., Bloom D., Torrealba J., Brahmbhatt R., Chang Z., Sollinger H.W., et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008, 8:1529-1536.
52. Miyara M., Yoshioka Y., Kitoh A., Shima T., Wing K., Niwa A., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
53. Kreijveld E., Koenen H.J.P.M., Klasen I.S., Hilbrands L.B., Joosten I. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007, 7:249-255.
54. Wang Z., Xiao L., Shi B.Y., Qian Y.Y., Bai H.W., Chang J.Y., et al. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation. Transpl Immunol 2008, 19:69-73.
55. Baan C.C., van der Mast B.J., Klepper M., Mol W.M., Peeters A.M., Korevaar S.S., et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005, 80:110-117.
56. Bluestone J.A., Liu W., Yabu J.M., Laszik Z.G., Putnam A., Belingheri M., et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008, 8:2086-2096.